References
- Buchheim R. Lehrbuch der Arzneimittellehre. Voss, Leipzig 1859; 19
- Echt D. S., Liebson P. R., Mitchell L. B., Petres R. W., Obias‐Manno D., Barker A. H., Friedman L., Green H. L., Huther M. L., Richardson D. W. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac arrhythmia Suppression Trial. N. Engl. J. Med. 1991; 324: 781–788, [PUBMED], [INFOTRIEVE]
- Editorial. Investing in children for a better future. The Lancet 2003; 362(9394)1427, [CROSSREF]
- Guyatt G., Sackett D., Taylor D. W., Chong J., Roberts R., Pugsley S. Determining optimal therapy—randomised trials in individual patients. N. Engl. J. Med. 1986; 314: 889–892, [PUBMED], [INFOTRIEVE]
- Habermann E. Therapeutics—progress and control. An epistemological approach. Theor. Surg. 1988; 2: 204–208
- Habermann E. Wie wissenschaftlich ist unsere Arzneitherapie?. Med. Welt 1995; 46: 1–7
- Jonas H. Das Prinzip Verantwortung. Versuch einer Ethik für die technologische Zivilisation. Suhrkamp Frankfurt am Main. 1984; 61–64
- Koch K. Hypertonie alpha‐rezeptorenblocker gestoppt. Deutsches Ärzteblatt 1997; 13: 648
- Lemonick M. D. Gene mapper. the bad boy of science has jump‐started a biological revolution. Time Europe. December 25, 2001; Vol. 156: 26
- Martini P. Methodenlehre der Klinischen Prüfung. Springer Verlag. 1932
- Medical Research Council Investigation. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 1948; 2: 769
- Nash J. M. Battle pending. Time. April 17, 2000; Vol. 155: 15
- National Institute of Health (NIH). NHLBI study finds traditional diuretics better than newer medicines for treating hypertension. December 17, 2002, http://www.nhlbi.nih.gov.
- Roots I., Gerloff T., Meisel C., Kirchheiner J., Goldammer M., Kaiser R., Laschinski G., Brockmöller J., Cascorbi I., Kleeberg U., Hildebrandt A. G. Pharmacogenetics‐Based New Therapeutic Concepts. 2004, T & F Informa plc
- Schmiedeberg O. Grundriss der Pharmakologie. F. C. W. Vogel, Leipzig 1909; 12
- Stille G. Der weg der arznei. Von der Materia Medica zur pharmakologie. G. Braun, Karlsruhe 1994
- Temple R. Trends in pharmaceutical developments. Drug Inf. J. 1993; 27: 355–366
- Trouiller P., Olliaro P., Torreele E., Orbinski J., Laing R., Ford N. Drug development for neglected diseases: a deficient market and a public health policy failure. The Lancet 2002; 359: 2188–2194, [CROSSREF]
- Virchow R. Über die Standpunkte in der wissenschaftlichen Medizin. Virchows Arch. 1847; 1: 3–19
- World Health Organization. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000–2003. Geneva. 2002, WHO/HTP/EDM2000.Http://www.who.int/medicines/strategy.pdf (accessed March 2, 2002)